Press releases

Genoskin is pleased to announce that its primary human mast cells will now be available to customers in North America, marking a key milestone in the company’s commercial development. This launch gives pharmaceutical and biotechnology researchers faster and more direct access to predictive, human-relevant immune cells for drug testing and safety assessment.

Genoskin strengthens governance with appointment of industry leader Fabrice Bouteille, a strategic milestone reinforcing independence, global growth, and leadership in human-relevant research.

At the 2026 annual meeting of the Society Of Toxicology (SOT), we will present new data demonstrating the value of our HypoSkin® ex vivo human skin platform as a translational human-based New Approach Methodology (NAM) for early safety assessment. The poster, developed in collaboration with argenx, will highlight how our platform can support early local tolerance screening and help reduce reliance on animal testing in formulation safety evaluation.

We are excited to announce that Genoskin, a leader in developing ex vivo human skin platforms for testing drugs and medical devices, has raised $8.7 million (€8M) in Series A funding. The investment will fuel the company’s global expansion, enhance its service offerings, and further its mission to provide ethical, human-relevant alternatives to animal testing.

The landscape of vaccine research is undergoing an important transformation, thanks to the breakthroughs in mRNA vaccine technology.

Genoskin, a biotechnology company at the forefront of accelerating drug development, proudly announces the enhancement of its ISR Platform^® with the integration of AUDACY, a state-of-the-art bioinformatics-based analytical solution. The new ImmunoSafe: ISR Platform^® brings a transformative approach to assessing local toxicity in the realm of non-clinical platforms, specifically focusing on injection site reactions (ISR).